Genomic aberrations in the CDK-Rb-E2F pathway are prevalent in breast cancer, resulting in enhanced resistance to chemotherapy and targeted therapies, particularly in HER2-positive cancers [50]. This evidence concerns the gene RB1 and breast cancer.